At least 11 distinct functional classes of proteins-including the Raf serine/ threonine kinases and the p110 catalytic subunits of class I PI3Ks-have been implicated as effectors of the small GTPase Ras (Repasky et al., 2004) . Because of the frequent mutational activation of Ras in cancer and the vast number of its effectors (Figure 1) , there has been much debate regarding the most effective strategies to develop anti-Ras inhibitors. In this issue, Gupta et al. (2007) further validate the importance of p110α and the PI3K-Akt signaling pathway in Ras-induced tumorigenesis.
The majority of studies analyzing a role for effectors in Ras-mediated oncogenesis have been performed in cultured cells. For example, experiments in immortalized human epithelial cells ectopically expressing oncogenic Ras have shown that concurrent activities of Raf, PI3K, and Ral-GEF (guanine nucleotide exchange factor) effector pathways are required for Ras-mediated initiation of tumor growth. The PI3K pathway is also crucial for tumor maintenance . One recent study used RNA interference to demonstrate the necessity of the Ral-GEF-Ral pathway in tumorigenesis, invasion, and metastasis of KRAS mutation positive pancreatic carcinoma cell lines .
Genetically engineered mouse models have also validated the importance of Ras effectors (Repasky et al., 2004) . Mice deficient for the effectors Tiam1, PLCε, or Ral-GDS showed impaired tumor initiation when tested in skin tumorigenesis-induced by the carcinogen dimethybenzanthracine (DMBA)-in which H-Ras activation is causal and frequent. Genetic ablation of other Ras effectors, in particular of p110α and p110β, results in defective development, thus complicating analyses of their contributions to Ras-mediated cancer development. Furthermore, deficiency studies can only assess the requirement of a given factor for tumorigenesis and not the specific interactions involved. Thus, Gupta et al. (2007) engineered mice in which the endogenous PIK3CA gene encodes a mutant p110α protein that is enzymatically active, but cannot interact with Ras, to evaluate the role of this effector in endogenous normal and mutant Ras signaling.
To selectively ablate p110α interactions with Ras, Gupta et al. (2007) introduced missense mutations into the germline sequence specifying the Ras-binding domain of p110α. Viable mice homozygous for this PIK3CA mutant allele were obtained, indicating that this partial loss-of-function mutant of p110α was sufficient to support development. They then analyzed these PIK3CA mutants in two well-characterized Ras-driven tumor models. In the K-Ras LA2 mouse model (Johnson et al., 2001) , tumorigenesis is driven by endogenous levels of mutant K-Ras (G12D) expression, and these mice develop lung adenocarcinomas at a high frequency. When the K-Ras LA2 mice were crossed with mice homozygous for mutant PIK3CA, a striking 95% reduction in lung tumor forma-Ras interacts with many downstream effectors that regulate complex cytoplasmic signaling networks. In this issue, Gupta et al. (2007) use mouse models of Ras-mediated tumorigenesis to show that the interaction of Ras with a single isoform of phosphatidylinositol 3-kinase (PI3K), called p110α (PIK3CA), is critical for tumor formation. This result will stimulate reevaluation of pharmacological approaches to target Ras for cancer treatment.
tion was observed. Second, when PIK3CA mutant mice were subjected to DMBA-induced carcinogenesis, a near-complete reduction in H-Rasdriven tumor formation was seen. Taken together, these observations argue that p110α is a critical effector for Ras-driven tumorigenesis in two distinct tissues.
The interpretation of the Gupta et al. study may be complicated by the importance of normal Ras signaling through p110α in normal host tissue. Mice homozygous for mutant PIK3CA exhibited in the lymphatic vasculature defective branching that markedly reduced viability at birth. Interestingly, this defect is similar to one seen previously in vascular endothelial growth factor C heterozygous null mice. Because of potential abnormalities caused by the PIK3CA mutation, it is possible that reduced Rasdriven tumor formation and growth in these mice may be partly due to altered responses of the tumor microenvironment. However, transformation assays in PIK3CA mutant mouse embryo fibroblasts derived from homozygous PIK3CA mutant embryos showed resistance to Ras transformation unlike their wild-type counterparts supporting a cellautonomous effect on mutant Ras signaling.
The importance of PI3K effector signaling in Ras-induced tumorigenesis that is suggested by this study argues against the perception of the Raf-MEK-ERK pathway being of prime if not sole importance, a concept that has been strengthened by the nonoverlapping frequency of RAS and BRAF mutations observed in melanomas and other cancers (Davies et al., 2002) . In vitro experiments demonstrated Ras activation of the Raf-MEK-ERK cascade in mouse embryo fibroblasts isolated from the p110α mutant mice. This result argues that, in this setting, Ras-mediated tumorigenesis cannot be driven by activation of Raf alone.
Alternatively, the effectors critical for Ras-induced tumorigenesis may be cell type specific, and Raf is not essential for lung adenocarcinoma development.
Another issue emphasized by this study is the functional diversity of the p110α and p110β isoforms, which are both Ras effectors, yet Gupta et al. reveal that p110β cannot efficiently support Ras-mediated activation of Akt. This observation mirrors those showing that Ras failed to effectively activate p110β in cell culture (Rodriguez-Viciana et al., 2004) . Thus, in addition to the unique mutational activation of p110α but not p110β in human cancers (Samuels et al., 2004) , cell-culture and mouse-model studies have also identified functional differences between these related p110 isoforms.
This study prompts several important future questions. First, will mice expressing Ras binding-deficient mutants of Tiam1, Ral-GDS, or PLCε show the same impaired Ras-induced tumorigenesis observed in mice deficient in effector expression? A similar evaluation with mice expressing Ras binding-deficient Raf isoforms will also be important to pursue. Second, will Ras-driven oncogenesis in other mouse cancer models-in particular in K-Ras-induced pancreatic tumor formation models (Aguirre et al., 2003; Hingorani et al., 2003) -also require p110α? The obligatory role for K-Ras activation in pancreatic tumors, coupled with the lack of effective therapeutic options for this deadly cancer, emphasizes the need to understand Ras in this cellular context. Third, these studies address the importance of PI3K signaling in the initiation of tumorigenesis. For effective therapy of pre-existing cancers, will the PI3K effector pathway also be required for tumor maintenance? This issue can be addressed by conditional expression of the mutant PIK3CA allele, which should reveal whether therapies targeted against PI3K and Akt (now entering clinical trials) will be an effective strategy for treating human cancers, particularly those of the lung, colon, and pancreas where 
. Effectors of Ras-Mediated Oncogenesis
Members of at least five functional classes of effectors have been implicated in Ras-mediated growth transformation and oncogenesis. The best studied is the Raf serine/threonine kinases (c-Raf-1, A-Raf, B-Raf). Raf phosphorylates and activates the MEK1 and MEK2 kinases, which phosphorylate and activate the ERK1 and ERK2 MAPKs. The next best characterized are the p110 (α, β, δ, and γ) catalytic subunits of the class I PI3Ks. PI3K kinases convert phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ), which promotes activation of multiple signaling proteins, including PDK1-mediated phosphorylation and activation of the AKT serine/threonine kinase. Four guanine nucleotide exchange factors (GEFs, which promote formation of the active, GTP-bound form of small GTPases) are activators of the RalA and RalB small GTPases (Ral-GDS, Rgl, Rgl2/Rlf, and Rgl3). The GEF Tiam1 (and the related Tiam2) activates the Rac small GTPase. Finally, Ras activation of phospholipase C epsilon (PLCε) catalyzes conversion of phosphatidylinositide (4,5) biphosphate to the second messengers, diacylglycerol (DAG) and inositol (1,4,5)-triphosphate (IP 3 ), resulting in DAG-mediated activation of protein kinase C (PKC) and mobilization of intracellular calcium ions, respectively.
RAS mutations are most prevalent. Recent results in human tumor cellculture models suggest that inhibition of the Raf-MEK-ERK cascade alone is not an effective strategy for treating tumors with RAS mutations, and that perhaps concurrent inhibition of other effector pathways is needed. Finally, will these results from mouse models accurately reflect the mechanisms of Ras-mediated oncogenesis in human tumors? Answers to these questions will be needed before the "right" strategy to target Ras signaling for cancer treatment will be realized.
Many living organisms have an internal clock that tracks the time of day even in the absence of external cues. This feat is accomplished by an internal transcription-translation-degradation cycle that is carefully tuned to produce circadian rhythms that are almost 24 hr in length. Given that transcriptional regulation is tightly controlled by the clock, it is reasonable to assume that degradation should also be tightly Two members of the PERIOD family, PER1 and PER2, and two members of the cryptochrome family, CRY1 and CRY2, are core proteins in the mammalian clock. The transcription of genes encoding these proteins is regulated by a heterodimeric transcription factor complex, which usually is the CLOCK protein bound to MOP3/ BMAL1. The CRY proteins associate with PERs and repress CLOCK/ BMAL1. As PERs and CRYs accumulate, their synthesis decreases; when PERs and CRYs are subsequently degraded, the transcription of their genes is derepressed. This cycle takes a day.
Accurate clock timing requires the orderly transcription, translation, assembly, nuclear import, and then degradation of the PER and CRY proteins (Gallego and Virshup, 2007) . A number of studies demonstrate that posttranslational modifications and targeted protein destruction are critical elements for correct timing. Two well-studied mammalian clock mutants-PER2/ FASPS (S662G) in humans and CKIε tau in hamsters-affect PER protein degradation. These circadian mutations decrease the stability of the PER proteins, either by direct mutation of PER2 (S662G) 
